Sunshine Biopharma Inc. Director Andrew Keller Won't Seek Re‑election

What Happened Sunshine Biopharma Inc. (SBFM) filed an 8‑K on August 28, 2026 reporting that on August 25, 2026 Dr. Andrew Keller notified the company he will not be seeking or accepting re‑election to the Board of Directors. Dr. Keller will serve through the end of his current term, which expires at the company’s next annual shareholder meeting.

Key Details

• Filing: Form 8‑K filed August 28, 2026 (Item 5.02 — Departure of Directors or Certain Officers).
• Notification date: August 25, 2026.
• Director: Dr. Andrew Keller will not seek or accept re‑election.
• Term: Dr. Keller’s current term ends at the next annual shareholder meeting; the filing does not name a replacement.

Why It Matters Board membership affects corporate oversight and governance. This filing informs investors that one director will leave at the end of his term, which may lead to a board vacancy or a future nominee to fill the seat. Investors should watch for subsequent proxy statements or 8‑Ks announcing any board nominees or other governance changes.